UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 18, 2009

 

Callisto Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

 

420 Lexington Avenue, Suite 1609

New York, New York 10170

(Address of principal executive offices)

 

Registrant’s telephone number, including area code: (212) 297-0010

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o   Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 1.01        Entry into a Material Definitive Agreement.

 

On December 30, 2008, Callisto Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase and exchange agreement (“Purchase Agreement”) with several investors, each of whom holders of record as of November 4, 2008 of outstanding warrants to purchase shares of the Company’s common stock,  exercisable at $0.50 or $0.70 per share until August 2, 2010 (“Series B Warrants”). The Series B Warrants were issued in connection with the private placement of the Company’s Series B Preferred Shares on August 2, 2007.    Pursuant to the Purchase Agreements we issued $201,905.26 of an authorized $500,000 11% Secured Notes due April 15, 2010 (“11% Notes”) with no discount in December 2009, which was previously reported on Form 8-K.  On February 3, 2009, the Company closed on an additional $51,377.60 of 11% Notes.

 

On June 18, 2009, the Company issued an additional $349,880.16 of 11% Notes to several investors pursuant to Purchase Agreements (the “June 2009  Closing”).  Interest on the 11% Notes is due on maturity, whether on April 15, 2010 or by acceleration.   In consideration of the increased subscription for the 11% Notes, the Company entered into an Amended and Restated Security Agreement pursuant to which it pledged 2,292,265 shares of the common stock of Synergy Pharmaceuticals, Inc. owned by the Company as payment for the 11% Notes, as well as an additional security agreement granting all of the holders of the 11% Notes a security interest in technology acquired by the Company in December 2008.

 

The Company issued to the purchasers of the 11% Notes, an aggregate of 69,089,049 common stock purchase warrants (“New Warrants”) of which 40,236,218 were issued June 18, 2009 and the purchasers of the 11% Notes surrendered 26,938,800 outstanding Series B Warrants for cancellation. The New Warrants have an exercise price, subject to certain adjustments, of $0.02 per share and are exercisable at any time on or prior to December 31, 2016. The New Warrants do not grant the holders thereof any voting or other rights of our stockholders.

 

Upon the occurrence of certain events of default defined in the 11% Notes, including events of default under the transaction documents related to the financing, the full principal amount of the 11% Notes, together with interest and other amounts owing, become immediately due and payable.

 

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

 

The disclosure provided in Item 1.01 of this Form 8-K is hereby incorporated by reference into this Item 2.03 with respect to the terms and sale of, and the financial obligations created by, the 11% Notes.

 

Item 3.02        Unregistered Sales of Equity Securities.

 

The disclosure provided in Item 1.01 of this Form 8-K is hereby incorporated by reference into this Item 3.02 with respect to the terms and sale of the 11% Notes and the exchange of New Warrants for outstanding Series B Warrants. Each of the purchasers represented that they were accredited investors and the Company did not engage a broker or make any general solicitation in connection with the sale of the securities. The sale of the 11% Notes and issuance of the New Warrants were made pursuant to Section 4(2) of the Securities Act of 1933, as amended.  The Company intends to use the net proceeds from the sale of the securities for working capital and general corporate purposes.

 

2

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated:  June 24, 2009
	CALLISTO PHARMACEUTICALS, INC.
	By:	/s/ Gary S. Jacob
		Gary S. Jacob, Ph.D.
		Chief Executive Officer

 

3